Elimination of Hypoglycemia From the Lives of People Affected by Diabetes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Iatrogenic hypoglycemia is a problem for people affected by diabetes (1). It causes recurrent morbidity in most people with type 1 diabetes and many with advanced type 2 diabetes, and it is sometimes fatal. It generally precludes maintenance of euglycemia over a lifetime of diabetes and thus full realization of the vascular benefits of glycemic control. And, it compromises defenses against subsequent falling plasma glucose concentrations and therefore causes a vicious cycle of recurrent hypoglycemia. Hypoglycemia in diabetes is fundamentally iatrogenic, the result of therapeutic hyperinsulinemia caused by treatment with a sulfonylurea, a glinide, or insulin. But because of the effectiveness of the normal glucose counterregulatory mechanisms, hypoglycemia is typically the result of the interplay of therapeutic hyperinsulinemia and compromised physiological and behavioral defenses against falling plasma glucose concentrations in people with diabetes (1). The compromised physiological defenses include loss of the normal decrements in insulin, increments in glucagon, and increments in epinephrine as glucose levels fall in absolute endogenous insulin deficient diabetes (1). Loss of decrements in insulin and of increments in glucagon develop early in people with type 1 diabetes but only later in people with type 2 diabetes. In view of increasing evidence that β-cell insulin secretion normally restrains α-cell glucagon secretion (2) and that a decrease in insulin normally signals an increase in glucagon secretion during hypoglycemia (3), loss of both the insulin and the glucagon responses is plausibly attributable to β-cell failure (1). That construct fits nicely with the fact that iatrogenic hypoglycemia becomes a major problem early in people with type 1 diabetes but only later in people with type 2 diabetes (1). Given the evidence that insulin also acts on the hypothalamus to restrain glucagon secretion, there may also be a central nervous system component to the loss of the glucagon response …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
Currie, C. J., Peters, J. R., Tynan, A., Evans, M., Heine, R. J., Bracco, O. L., Zagar, T., & Poole, C. D. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61969-3 · Cited by 874 · cited 1×
“Increased mortality has been reported during more aggressive glucose–lowering therapy compared with less aggressive glucose–lowering therapy in individuals with type 2 diabetes (13), in those with hyperglycemia in intensive care units (14), and in individuals with type 2 diabetes and A1C levels in the lower and higher…”
Lachin, J. M., Genuth, S., Nathan, D. M., Zinman, B., Rutledge, B. N., & for the DCCT/EDIC Research Group (2008) · Diabetes · doi:10.2337/db07-1618 · Cited by 555 · cited 1×
“In addition, there are long-term benefits from reducing A1C from higher to lower—albeit still above recommended—levels (16).”
BackgroundTong, Q., Ye, C., McCrimmon, R. J., Dhillon, H., Choi, B., Kramer, M. D., Yu, J., Yang, Z., Christiansen, L. M., Lee, C. E., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.04.001 · Cited by 413 · cited 1×
“Although ventromedial hypothalamic glutamate release is thought to mediate the sympathoadrenal response to hypoglycemia in rats (32), antagonism of glutamate signaling with the N-methyl-D-aspartate (NMDA) receptor antagonist memantine (33) or with the amino-3-hydroxy-5-methy1–4-isoazol propionate (AMPA) receptor antag…”
BackgroundA Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes
El-Khatib, F. H., Russell, S. J., Nathan, D. M., Sutherlin, R. G., & Damiano, E. R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000619 · Cited by 403
Fanelli, C. G., Epifano, L., Rambotti, A. M., Pampanelli, S., Di Vincenzo, A., Modarelli, F., Lepore, M., Annibale, B., Ciofetta, M., Bottini, P., et al. (1993) · Diabetes · doi:10.2337/diab.42.11.1683 · Cited by 398
Fanelli, C., Pampanelli, S., Epifano, L., Rambotti, A. M., Di Vincenzo, A., Modarelli, F., Ciofetta, M., Lepore, M., Annibale, B., Torlone, E., et al. (1994) · Diabetologia · doi:10.1007/bf00399801 · Cited by 212
Raju, B., & Cryer, P. E. (2005) · Diabetes · doi:10.2337/diabetes.54.3.757 · Cited by 155 · cited 1×
“However, oral diazoxide suppresses the glucagon response and has no effect on the epinephrine response to hypoglycemia in humans (31).”
BackgroundSelf-citationActivation of human medial prefrontal cortex during autonomic responses to hypoglycemia
Teves, D., Videen, T. O., Cryer, P. E., & Powers, W. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307048101 · Cited by 138
Self-citationHypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention
Cryer, P. (2016) · doi:10.2337/9781580406499 · Cited by 104
Self-citationAttenuation of Counterregulatory Responses to Recurrent Hypoglycemia by Active Thalamic Inhibition
Arbelaez, A. M., Powers, W. J., Videen, T. O., Price, J. L., & Cryer, P. E. (2008) · Diabetes · doi:10.2337/db07-1329 · Cited by 92
Self-citationThe effect of caffeine on glucose kinetics in humans - influence of adrenaline
Battram, D. S., Graham, T. E., Richter, E. A., & Dela, F. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.097444 · Cited by 44 · cited 1×
“Among other possibilities, adenosine antagonists, such as caffeine, raise catecholamine levels and enhance symptoms of hypoglycemia in people with diabetes (25,26).”
BackgroundAdrenergic mediation of hypoglycemia-associated autonomic failure
Ramanathan, R., & Cryer, P. E. (2011) · Diabetes · doi:10.2337/db10-1374 · Cited by 42
Self-citationThe effect of modafinil on counter-regulatory and cognitive responses to hypoglycaemia
Smith, D., Pernet, A., Rosenthal, J. M., Bingham, E. M., Reid, H., Macdonald, I. A., & Amiel, S. A. (2004) · Diabetologia · doi:10.1007/s00125-004-1513-5 · Cited by 31 · cited 1×
“Modafinil, a drug that decreases extracellular -aminobutyric acid levels, increases symptoms of hypoglycemia (27).”
Background
Cited by
Mechanisms of hypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1215228 · Cited by 433
Self-citationCharleer, S., De Block, C., Van Huffel, L., Broos, B., Fieuws, S., Nobels, F., Mathieu, C., & Gillard, P. (2020) · Diabetes Care · doi:10.2337/dc19-1610 · Cited by 261
Death during intensive glycemic therapy of diabetes: mechanisms and implications
Cryer, P. E. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.008 · Cited by 137
Self-citationRestoration of Self-Awareness of Hypoglycemia in Adults With Long-Standing Type 1 Diabetes
Leelarathna, L., Little, S. A., Walkinshaw, E., Tan, H. K., Lubina-Solomon, A., Kumareswaran, K., Lane, A. P., Chadwick, T., Marshall, S. M., Speight, J., et al. (2013) · Diabetes Care · doi:10.2337/dc13-1004 · Cited by 56
Metadata
- Authors
- Cryer, P. E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-01-01
- Volume
- 60
- Issue
- 1
- Pages
- 24-27
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2126453854
- Cited by
- 32
- References
- 14
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.